Hypofractionated Stereotactic Re-Irradiation With Pembrolizumab and Bevacizumab in Patients With Recurrent High-Grade Gliomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Hypofractionated Stereotactic Re-Irradiation With Pembrolizumab and Bevacizumab in Patients With Recurrent High-Grade Gliomas: Results From a Phase I Study
Neuro-oncology 2021 Apr 12;23(4)677-686, S Sahebjam, PA Forsyth, ND Tran, JA Arrington, R Macaulay, AB Etame, CM Walko, T Boyle, EN Peguero, M Jaglal, S Mokhtari, H Enderling, N Raghunand, T Gatewood, W Long, JL Dzierzeski, B Evernden, T Robinson, MC Wicklund, S Kim, ZJ Thompson, DT Chen, P Chinnaiyan, HM YuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.